Neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN) Formulary Central

Mirdametinib Clinical Trial Information

ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic NF1-PN

Evaluation of the Dispersible Tablet and Capsule Formulations of Mirdametinib in Children With NF1-PN: ReNeu Trial

Health-Related Quality of Life (HRQoL) in Adults and Children With NF1-PN Treated With Mirdametinib in the Pivotal Phase 2b ReNeu Trial

Addressing Skin Adverse Events During Mirdametinib Treatment in Patients With NF1-PN: Guidance From a Multidisciplinary Group of Experts Involved in the ReNeu Trial

Pivotal, Phase 2b ReNeu Trial of Mirdametinib in Children and Adults With NF1-PN: A Spotlight on Patients Achieving Deep Response

Utilization Management Considerations

Information to Consider for Mirdametinib Coverage

Clinical Impact of Disease

Neurofibromatosis type 1

Clinical and genetic aspects of neurofibromatosis 1

Neurofibromatosis: A Review of NF1, NF2, and Schwannomatosis

Manuscripts Permissions

Mirdametinib is an investigational product and has not been approved by the US Food and Drug Administration (FDA). The safety and efficacy of mirdametinib have not been established.